VARIANT: 238v1
Help
Entry
238v1 Variant
Name
EML4-ALK fusion
Gene
ALK
ALK receptor tyrosine kinase [KO:
K05119
]
Organism
hsa_var Human gene variants (Homo sapiens)
Variation
inversion inv(2)(p21p23)
COSF:
473
463
474
Network
nt06210
ERK signaling
nt06214
PI3K signaling
nt06219
JAK-STAT signaling
nt06220
Calcium signaling
nt06266
Non-small cell lung cancer
Element
N00007
EML4-ALK fusion kinase to RAS-ERK signaling pathway
N00025
EML4-ALK fusion kinase to PLCG-ERK signaling pathway
N00047
EML4-ALK fusion kinase to PI3K signaling pathway
N00105
EML4-ALK fusion kinase to Jak-STAT signaling pathway
N10003
First-generation tyrosine kinase inhibitor to ALK fusion
Drug target
Crizotinib:
D09731
<JP/US>
Reference
PMID:
26755435
Authors
Bayliss R, Choi J, Fennell DA, Fry AM, Richards MW
Title
Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs.
Journal
Cell Mol Life Sci 73:1209-24 (2016)
DOI:
10.1007/s00018-015-2117-6
Reference
PMID:
17625570
Authors
Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H
Title
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
Journal
Nature 448:561-6 (2007)
DOI:
10.1038/nature05945
LinkDB
All DBs
VARIANT: 238v2
Help
Entry
238v2 Variant
Name
First generation TKI-resistant ALK1 mutation
Gene
ALK
ALK receptor tyrosine kinase [KO:
K05119
]
Organism
hsa_var Human gene variants (Homo sapiens)
Variation
mutation I1171T
COSM:
4381100
Variation
mutation C1156Y
COSM:
99136
Variation
mutation F1174L
COSM:
28061
Variation
mutation L1196M
COSM:
99137
Variation
mutation G1269A
COSM:
1169707
Variation
mutation G1202R
COSM:
144250
4422789
Variation
mutation S1206Y
COSM:
144251
4422788
Network
nt06210
ERK signaling
nt06214
PI3K signaling
nt06219
JAK-STAT signaling
nt06220
Calcium signaling
nt06266
Non-small cell lung cancer
Element
N00007
EML4-ALK fusion kinase to RAS-ERK signaling pathway
N00025
EML4-ALK fusion kinase to PLCG-ERK signaling pathway
N00047
EML4-ALK fusion kinase to PI3K signaling pathway
N00105
EML4-ALK fusion kinase to Jak-STAT signaling pathway
N10004
Second/third-generation tyrosine kinase inhibitor to ALK fusion
Drug target
Alectinib (
DG01625
):
D10450
<JP/US>
Brigatinib:
D10866
<JP/US>
Ceritinib:
D10551
<JP/US>
Lorlatinib:
D11012
<JP/US>
Reference
PMID:
26755435
Authors
Bayliss R, Choi J, Fennell DA, Fry AM, Richards MW
Title
Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs.
Journal
Cell Mol Life Sci 73:1209-24 (2016)
DOI:
10.1007/s00018-015-2117-6
Reference
PMID:
21030459
Authors
Sasaki T, Okuda K, Zheng W, Butrynski J, Capelletti M, Wang L, Gray NS, Wilner K, Christensen JG, Demetri G, Shapiro GI, Rodig SJ, Eck MJ, Janne PA
Title
The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.
Journal
Cancer Res 70:10038-43 (2010)
DOI:
10.1158/0008-5472.CAN-10-2956
LinkDB
All DBs
DBGET
integrated database retrieval system